EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Hospital Universitario Arnau de Vilanova
Lleida, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (11)
2022
2021
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2020
-
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
Cancer Treatment Reviews, Vol. 83
-
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial
Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
2019
-
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer
European Journal of Cancer Care, Vol. 28, Núm. 6
-
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial
BMC Medicine, Vol. 17, Núm. 1
2018
-
Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2012
-
Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
Journal of Clinical Oncology, Vol. 30, Núm. 13, pp. 1484-1491